4D Molecular Therapeutics, Inc. (FDMT) Tops Q3 EPS by 37c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q3 EPS of ($0.24), $0.37 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $20.2 million versus the consensus estimate of $9.18 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Buffalo airport blames circuit fault, not shortage, for 3 flight delays
• flyExclusive names Brian P. Reid as chief commercial officer